{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"New Data from Randomized Phase III Trials Do Not Alter Standard Therapy for Brain Cancer in the Elderly - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"K7LdZgG7IH\"><a href=\"https:\/\/themedicalxchange.com\/en\/2010\/06\/04\/2010-american-society-of-clinical-oncology-asco-an\/\">New Data from Randomized Phase III Trials Do Not Alter Standard Therapy for Brain Cancer in the Elderly<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/2010\/06\/04\/2010-american-society-of-clinical-oncology-asco-an\/embed\/#?secret=K7LdZgG7IH\" width=\"600\" height=\"338\" title=\"&#8220;New Data from Randomized Phase III Trials Do Not Alter Standard Therapy for Brain Cancer in the Elderly&#8221; &#8212; The Medical Xchange\" data-secret=\"K7LdZgG7IH\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2010\/06\/ASCO_GRAPH1_EN.png","thumbnail_width":792,"thumbnail_height":595,"description":"Chicago \u2013 In glioblastoma, the gold standard of an initial combination of radiotherapy and chemotherapy followed by adjuvant chemotherapy does not appear to have been altered by new results from two phase III studies conducted in elderly patients. Presented as late breaker data at this year\u2019s ASCO meeting, the studies are part of an ongoing effort to identify the best modalities for improved outcomes in the context of acceptable tolerability. Both studies were conducted in newly diagnosed elderly patients but ultimately served as a platform of debate about the definition of elderly and the role of age as a discriminator for treatment independent of performance status. The results of the studies underscore the complex balance between median overall survival benefit and quality of life. Relative to age, discriminators such as O-6-methylguanine DNA methyltransferase (MGMT) promoter methylation status may be more useful for selecting intensity of therapy in an effort to extend survival at an acceptable level of tolerability."}